Back to Search
Start Over
Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
- Source :
- Clinical & Experimental Immunology; Jun2022, Vol. 208 Issue 3, p316-322, 7p
- Publication Year :
- 2022
-
Abstract
- Immune Check-Point Inhibitors (ICIs) have shown remarkable promise in treating tumors, including non-small cell lung cancer (NSCLC). Nevertheless, the treatment response rate is low. Studies have found that the high expression of exosomal PD-L1 is one of the reasons for the low treatment response. Therefore, this study focused on the relationship between the exosomal PD-L1 and the clinical response to immunotherapy in NSCLC patients to evaluate whether it could be used as a biomarker to predict the efficacy of ICIs. In this study, clinical information and blood samples of 149 NSCLC patients receiving ICIs were collected. The expression level of exosomal PD-L1 was detected by enzyme-linked immunosorbent assay method, and the relationship between exosomal PD-L1 and the efficacy of ICIs was explored. Overall, our study found that the expression level of exosomal PD-L1 was lower at pre-treatment, or the max fold increasing change higher at 3–6 weeks had a higher disease control rate and longer progression-free survival. It revealed that the exosomal PD-L1 was associated with the treatment response of patients using ICIs and provided a new tool for the evaluation of clinical efficacy of lung cancer immunotherapy. This study revealed that exosomal PD-L1 was associated with the treatment response of patients using ICIs. The level of pre-treatment and the maximum fold increasing change of exosomal PD-L1 stratified clinical responders and non-responders. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00099104
- Volume :
- 208
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Clinical & Experimental Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 160116896
- Full Text :
- https://doi.org/10.1093/cei/uxac045